Cognitive

Cerebrolysin Dosage Protocol

A porcine brain-derived neuropeptide mixture approved in multiple countries for stroke and dementia. Complete dosing guide, clinical evidence, and peer-reviewed references.

Last reviewed March 2025 · 2 cited sources

Preparation

Pre-mixed / No reconstitution required

Daily dose range

5–30 mL IV daily (titrated)

Administration

IV / IM only

Storage (lyophilized)

Freeze at Refrigerate liquid vial · Reconstituted: N/A -pre-dissolved · Use within Use as supplied

Dosing & Administration Guide

Cerebrolysin is supplied as a pre-mixed solution and does not require reconstitution. Follow the titration schedule below.

Phase	Daily dose	U-100 units	Injection volume
Standard	5–30 mL IV daily	Pre-dissolved liquid	5–30 mL

Route: IV / IM only · Frequency: Daily IV/IM for 10–21 day courses · Cycle: 10–21 days

Research use only. This protocol is derived from published preclinical and early-phase clinical literature. Cerebrolysin is not FDA-approved for human use. This information is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide protocol.

Supplies Needed

Estimates below assume the titration schedule listed above.

Cerebrolysin vials (60 mg each)

Per cycleAs needed per titration

U-100 insulin syringes

8 weeks56 syringes

12 weeks84 syringes

16 weeks112 syringes

Bacteriostatic water (10 mL bottles)

Per vialN/A mL needed

Alcohol swabs (100-count boxes)

8 weeks2 boxes (~112 swabs)

12 weeks2 boxes (~168 swabs)

16 weeks3 boxes (~224 swabs)

Storage Instructions

Lyophilized (dry powder)

Refrigerate liquid vial

Store frozen in dry, dark conditions. Minimize humidity exposure. Stable for 12–24 months when properly stored.

Reconstituted (in solution)

N/A -pre-dissolved

Refrigerate after reconstitution. Use within Use as supplied. Do not refreeze reconstituted solution -freeze-thaw cycles degrade peptide integrity.

Allow refrigerated vials to reach room temperature before opening to minimize condensation uptake. Always inspect for cloudiness or particulates before use -discard if present.

Verified Source

Looking for research-grade peptides? Pacific Edge Labs carries a growing catalog of high-purity compounds with third-party lab results published on each product page.

Why Pacific Edge Labs

High-purity compounds with third-party lab results available on the website
Consistent quality control with ISO-aligned handling and documentation
Fast, discreet shipping with proper handling and packaging

Browse Pacific Edge Labs →

Cerebrolysin is not currently in the PEL catalog -check back for availability.

How Cerebrolysin Works

Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and amino acids derived from porcine brain tissue through controlled enzymatic proteolysis. The preparation contains neurotrophic factor-like peptides that cross the blood-brain barrier and exhibit biological activity resembling BDNF, NGF, and GDNF -key mediators of neuronal survival, differentiation, and synaptic plasticity.^[1]

Cerebrolysin is approved in Europe, Asia, and Russia for the treatment of stroke, Alzheimer's disease, and vascular dementia, supported by multiple randomized controlled trials. A Cochrane meta-analysis found evidence of cognitive improvement in Alzheimer's patients, though the authors noted variable study quality.^[2] It is administered exclusively via IV or IM injection -no reconstitution is required as it is supplied as a pre-dissolved liquid.

Observed Effects & Side Effect Profile

The following observations are derived from preclinical literature and limited early-phase human data. They do not constitute clinical claims.

Reported benefits (research literature)

Approved in 35+ countries for stroke and dementia -extensive clinical use history
Multiple RCTs demonstrate cognitive improvement in Alzheimer's disease
BBB-crossing neurotrophic factor-like activity supporting neuronal survival
No reconstitution required -supplied as ready-to-use liquid formulation

Known limitations & side effects

Not FDA-approved in the United States
Requires IV or IM administration -not suitable for subcutaneous self-injection
Dizziness, headache, and injection site pain reported in clinical trials
Porcine-derived -not suitable for individuals with pork protein allergies
Variable study quality noted in systematic reviews

Lifestyle Considerations

While the following suggestions are not protocol requirements, research on tissue repair and peptide efficacy consistently highlights these as factors that influence outcomes:

Protein intake. Collagen synthesis and tissue remodeling require adequate dietary protein. Research generally supports 1.6–2.2 g/kg/day during active recovery periods.

Sleep. The majority of tissue repair and growth hormone secretion occurs during deep sleep stages. 7–9 hours of quality sleep per night supports the biological environment in which recovery peptides operate.

Activity balance. Avoid complete immobilization (which impedes collagen remodeling) and overuse (which re-injures tissue). Progressive loading appropriate to the injury stage supports functional recovery.

Stress management. Elevated cortisol chronically impairs immune function and tissue repair. Evidence-based stress reduction techniques support the recovery environment.

Injection Technique

Standard subcutaneous injection guidance from clinical best-practice references.

Wash hands thoroughly. Clean your work surface. Gather all supplies before beginning.

Wipe the vial rubber stopper with a fresh alcohol swab. Allow it to dry completely before inserting a needle.

Draw the calculated dose volume into a sterile insulin syringe. Invert the syringe and tap to remove air bubbles; expel them before withdrawing the needle from the vial.

Select an injection site: abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm. Clean with a fresh alcohol swab and allow to dry.

Pinch a fold of skin between thumb and forefinger. Insert the needle at a 45–90° angle depending on body fat thickness -45° for leaner individuals, 90° for more subcutaneous tissue.

Do not aspirate. Current clinical guidelines do not recommend aspiration for subcutaneous injections. Inject slowly and steadily over 2–3 seconds.

Wait 3–5 seconds after the plunger bottoms out before withdrawing the needle at the same angle. Apply gentle pressure with a clean swab -do not rub vigorously.

Rotate injection sites systematically with every dose. Reusing the same site repeatedly causes lipohypertrophy (hardened fat tissue) which reduces absorption consistency.

Dispose of used needles and syringes immediately in a puncture-resistant sharps container. Never recap needles by hand.

Important Notes

⚠

Research use only. Cerebrolysin is not FDA-approved for human use. Human clinical data may be limited. Do not use without consulting a qualified healthcare professional.

◎

One syringe per injection. Never reuse needles or syringes. Each injection requires a fresh, sterile syringe to prevent contamination and infection risk.

⚠

IV/IM administration only -NOT for subcutaneous self-injection

⚠

Pre-dissolved liquid -no reconstitution needed

◎

Document your protocol. Record daily dose, injection site, and any observations. This supports consistency and allows you to identify patterns or issues over the course of the cycle.

◎

Inspect before each use. The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulates are visible.

References

All dosing recommendations and mechanism descriptions on this page are derived from the following peer-reviewed publications and regulatory documents.

PubMed 22514792

Bornstein NM et al. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders

pubmed.ncbi.nlm.nih.gov/22514792 ↗

PubMed 33515100

Muresanu DF et al. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes

pubmed.ncbi.nlm.nih.gov/33515100 ↗